Oncology Nursing News®

Blood Cancers

$FDA Grants Priority Review to Belantamab Mafodotin for Relapsed/Refractory Myeloma$

FDA Grants Priority Review to Belantamab Mafodotin for Relapsed/Refractory Myeloma

BY KRISTIE L. KAHL

Luspatercept Reduces Anemia in Patients With MDS

Luspatercept Reduces Anemia in Patients With MDS

BY BRITTANY COTE

After Years of Inactivity, AML Field Moves Forward

After Years of Inactivity, AML Field Moves Forward

BY ELLIE LEICK

ALL Field Continues to Progress, With CAR T-Cell and Other Therapies

ALL Field Continues to Progress, With CAR T-Cell and Other Therapies

BY JESSICA HERGERT

More Biosimilars Could Enter the Oncology Space

More Biosimilars Could Enter the Oncology Space

BY GINA COLUMBUS

There Are 'Tremendous Reasons to Be Hopeful' in Myeloma

There Are 'Tremendous Reasons to Be Hopeful' in Myeloma

BY SASCHA A. TUCHMAN, MD, MHS

Decrease Patient Stress: Keep MRD in the Academic Setting

Decrease Patient Stress: Keep MRD in the Academic Setting

BY BARRY PAUL, MD

Nurses Are Crucial in the Myeloma Treatment Team

Nurses Are Crucial in the Myeloma Treatment Team

BY JOSHUA RICHTER, MD

Reducing Transfusion Burden in Patients With Beta-Thalassemia

Reducing Transfusion Burden in Patients With Beta-Thalassemia

BY LYNNE LEDERMAN, PHD

CAR-T Therapy Is Promising for Older, Difficult-to-Treat Patients With NHL

CAR-T Therapy Is Promising for Older, Difficult-to-Treat Patients With NHL

BY HANNAH SLATER

External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc

OncNurse Resources

Newsroom
Continuing Education
Discussions
Web Exclusives

About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.